FDA Accepts Celcuity Application for REVTORPYK in Mutant Breast Cancer
The FDA set a June 25, 2027, target date to review Celcuity’s application for patients with PIK3CA-mutant breast cancer.
Makkler Newsroom · Nov 9, 04:51 PM · 1 min read
Celcuity Inc. CELC
NASDAQHealth TechnologyUnited States
$64.37+0.20 (+0.31%)
Market closed· · USD · Data may be delayed
- Day's range
- 61.7164.60
- 52-week range
- 53.54151.02
Financial health
– / 5
Analyst view · 13 firms
Buy13 buy · 0 hold · 0 sell
Avg. target $150.85 (+134.3%)
Prices may be delayed and are for informational purposes only - not investment advice.